clinical trial · NCT07737106
Phase I/II Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)
Sinovac Biotech Co., Ltd·phase1·completed·n = 50
InfluenzaInfluenza Vaccine (Split Virion), Inactivated (High Dose)Influenza Vaccine (Split Virion), Inactivated
brief summary
This is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.
started
Aug 21, 2025
primary completion
Sep 18, 2025
completion
Feb 24, 2026
last updated
Jul 30, 2026
detailed description
50 participants aged 60 years and older will be enrolled and randomly assigned in a 1:1 ratio to receive one dose of the investigational vaccine or the active control vaccine (Anflu®).
official title
A Randomized, Double-blind, Active-controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) in Adults Aged 60 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol